Cargando…
Liqui-Tablet: the Innovative Oral Dosage Form Using the Newly Developed Liqui-Mass Technology
In this study, an attempt was made to produce Liqui-Tablets for the first time. This was carried out through the compaction of naproxen Liqui-Pellets. The incentive to convert the novel Liqui-Pellet into Liqui-Tablet was due to the array of inherent advantages of the popular and preferred tablet dos...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7921041/ https://www.ncbi.nlm.nih.gov/pubmed/33650023 http://dx.doi.org/10.1208/s12249-021-01943-w |
_version_ | 1783658393876037632 |
---|---|
author | Lam, Matthew Asare-Addo, Kofi Nokhodchi, Ali |
author_facet | Lam, Matthew Asare-Addo, Kofi Nokhodchi, Ali |
author_sort | Lam, Matthew |
collection | PubMed |
description | In this study, an attempt was made to produce Liqui-Tablets for the first time. This was carried out through the compaction of naproxen Liqui-Pellets. The incentive to convert the novel Liqui-Pellet into Liqui-Tablet was due to the array of inherent advantages of the popular and preferred tablet dosage form. The study showed that naproxen Liqui-Tablet could be successfully produced and the rapid drug release rate (100% drug release ~ 20 min) could be achieved under pH 1.2, where naproxen is insoluble. It was observed that the different pH of the dissolution medium affected the trend of drug release from formulations with varying amounts of liquid vehicle. The order of the fastest drug-releasing formulations was different depending on the pH used. The presence of Neusilin US2 showed considerable enhancement in the drug release rate as well as improving Liqui-Tablet robustness and hardness. Furthermore, images from X-ray micro-tomography displayed a uniform distribution of components in the Liqui-Tablet. The accelerated stability studies showed acceptable stability in terms of dissolution profile. |
format | Online Article Text |
id | pubmed-7921041 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-79210412021-03-19 Liqui-Tablet: the Innovative Oral Dosage Form Using the Newly Developed Liqui-Mass Technology Lam, Matthew Asare-Addo, Kofi Nokhodchi, Ali AAPS PharmSciTech Research Article In this study, an attempt was made to produce Liqui-Tablets for the first time. This was carried out through the compaction of naproxen Liqui-Pellets. The incentive to convert the novel Liqui-Pellet into Liqui-Tablet was due to the array of inherent advantages of the popular and preferred tablet dosage form. The study showed that naproxen Liqui-Tablet could be successfully produced and the rapid drug release rate (100% drug release ~ 20 min) could be achieved under pH 1.2, where naproxen is insoluble. It was observed that the different pH of the dissolution medium affected the trend of drug release from formulations with varying amounts of liquid vehicle. The order of the fastest drug-releasing formulations was different depending on the pH used. The presence of Neusilin US2 showed considerable enhancement in the drug release rate as well as improving Liqui-Tablet robustness and hardness. Furthermore, images from X-ray micro-tomography displayed a uniform distribution of components in the Liqui-Tablet. The accelerated stability studies showed acceptable stability in terms of dissolution profile. Springer International Publishing 2021-03-01 /pmc/articles/PMC7921041/ /pubmed/33650023 http://dx.doi.org/10.1208/s12249-021-01943-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Article Lam, Matthew Asare-Addo, Kofi Nokhodchi, Ali Liqui-Tablet: the Innovative Oral Dosage Form Using the Newly Developed Liqui-Mass Technology |
title | Liqui-Tablet: the Innovative Oral Dosage Form Using the Newly Developed Liqui-Mass Technology |
title_full | Liqui-Tablet: the Innovative Oral Dosage Form Using the Newly Developed Liqui-Mass Technology |
title_fullStr | Liqui-Tablet: the Innovative Oral Dosage Form Using the Newly Developed Liqui-Mass Technology |
title_full_unstemmed | Liqui-Tablet: the Innovative Oral Dosage Form Using the Newly Developed Liqui-Mass Technology |
title_short | Liqui-Tablet: the Innovative Oral Dosage Form Using the Newly Developed Liqui-Mass Technology |
title_sort | liqui-tablet: the innovative oral dosage form using the newly developed liqui-mass technology |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7921041/ https://www.ncbi.nlm.nih.gov/pubmed/33650023 http://dx.doi.org/10.1208/s12249-021-01943-w |
work_keys_str_mv | AT lammatthew liquitablettheinnovativeoraldosageformusingthenewlydevelopedliquimasstechnology AT asareaddokofi liquitablettheinnovativeoraldosageformusingthenewlydevelopedliquimasstechnology AT nokhodchiali liquitablettheinnovativeoraldosageformusingthenewlydevelopedliquimasstechnology |